
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SARS-CoV-2 Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Codagenix
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Orphan Receoves MHRA Approval for Nasal COVID-19 Vaccine Trial
Details : The study will assess the safety and immunogenicity of a single-dose nasal vaccine candidate COVI-VAC in 48 healthy young adult volunteers.
Product Name : Covi-vac
Product Type : Vaccine
Upfront Cash : Inapplicable
December 14, 2020
Lead Product(s) : SARS-CoV-2 Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Codagenix
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CodaVax-COVID
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Codagenix
Deal Size : Undisclosed
Deal Type : Agreement
Open Orphan Awarded Contract from Codagenix Inc. New York USA for COVID-19 Vaccine Trial
Details : The deal aims at conducting a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, intranasal SARS-CoV-2 (COVID-19) vaccine candidate in 48 healthy young adult volunteers.
Product Name : CodaVax-COVID
Product Type : Vaccine
Upfront Cash : Undisclosed
July 28, 2020
Lead Product(s) : CodaVax-COVID
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Codagenix
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : OC43 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Orphan’s Cathal Friel on firm’s “milestone” human coronavirus challenge study (ORPH)
Details : For this human challenge study model, the common coronavirus strains such as OC43 and 229E, will provide an effective tool to obtain fast proof-of-concept data against this family of viruses.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
March 09, 2020
Lead Product(s) : OC43 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
